CLINICAL TRIALS PROFILE FOR METHYLPREDNISOLONE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for METHYLPREDNISOLONE
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT00977444 ↗ | Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment | Unknown status | National Council of Science and Technology, Mexico | Phase 2/Phase 3 | 2007-11-01 | Abstract Kondrium, is a pharmaceutical composition for the treatment of osteoarthritis (OA). This study was designed to evaluate the efficacy and safety of kondrium in the treatment of OA of knee. A 3 month, randomized, double-blind, active-controlled, parallel-group study will be carried out. 117 patients with OA of the knee will be randomized to receive 1 intra-articular monthly injection of 5 mL of one of the following: 75 mg/mL of Kondrium, 82.5 mg/mL of Kondriumf or 8 mg/mL of methylprednisolone once a month during 3 months. The primary efficacy variable will be the change from baseline to final assessment in the Western Ontario and McMaster University OA index (WOMAC subscale score for pain), and Lequesne´s functional index. |
| New Formulation | NCT00977444 ↗ | Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment | Unknown status | Nucitec | Phase 2/Phase 3 | 2007-11-01 | Abstract Kondrium, is a pharmaceutical composition for the treatment of osteoarthritis (OA). This study was designed to evaluate the efficacy and safety of kondrium in the treatment of OA of knee. A 3 month, randomized, double-blind, active-controlled, parallel-group study will be carried out. 117 patients with OA of the knee will be randomized to receive 1 intra-articular monthly injection of 5 mL of one of the following: 75 mg/mL of Kondrium, 82.5 mg/mL of Kondriumf or 8 mg/mL of methylprednisolone once a month during 3 months. The primary efficacy variable will be the change from baseline to final assessment in the Western Ontario and McMaster University OA index (WOMAC subscale score for pain), and Lequesne´s functional index. |
| New Formulation | NCT01267201 ↗ | A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form | Completed | Pfizer | Phase 1 | 2010-11-01 | A new formulation of methylprednisolone is being developed. A study is needed to determine the drug availability using the new formulation, a powder for reconstitution into a suspension, versus the current commercially available tablet formulation in healthy volunteers. |
| New Formulation | NCT01405131 ↗ | A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets | Withdrawn | Pfizer | Phase 1 | 2012-01-01 | A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for METHYLPREDNISOLONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000146 ↗ | Optic Neuritis Treatment Trial (ONTT) | Unknown status | National Eye Institute (NEI) | Phase 3 | 1988-07-01 | To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis. To determine the natural history of vision in patients who suffer optic neuritis. To identify risk factors for the development of multiple sclerosis in patients with optic neuritis. |
| NCT00000147 ↗ | Longitudinal Optic Neuritis Study (LONS) | Unknown status | National Eye Institute (NEI) | N/A | 1988-07-01 | To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis. To determine the natural history of vision in patients who suffer optic neuritis. To identify risk factors for the development of multiple sclerosis in patients with optic neuritis. |
| NCT00000579 ↗ | Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1994-09-01 | The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented. |
| NCT00000596 ↗ | Diffuse Fibrotic Lung Disease | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1978-06-01 | To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis. Also, to evaluate the use of intermittent, short-term, high-dose intravenous corticosteroids in patients with sarcoidosis. There were actually four separate clinical trials. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METHYLPREDNISOLONE
Condition Name
Clinical Trial Locations for METHYLPREDNISOLONE
Trials by Country
Clinical Trial Progress for METHYLPREDNISOLONE
Clinical Trial Phase
Clinical Trial Sponsors for METHYLPREDNISOLONE
Sponsor Name
